Chime Biologics
Latest round
- Series A
Last raised
- Dec 2025
Total raised
- $207M
Investors
- 4
About Chime Biologics
Based in Wuhan, China, and founded in 2013, Chime Biologics Limited provides biopharmaceutical development and manufacturing solutions. The company employs over 400 people. Chime Biologics Limited offers integrated solutions for early-stage drug development to late-stage clinical research and commercial cGMP (current good manufacturing) production. The company’s integrated platform offers cell Line development, process development, process transfer, quality control and assurance (QC/QA), protein science characterization, clinical manufacturing (DS/DP), commercial manufacturing (DS/DP), material management & logistics, and regulatory support. Chime Biologics also provides biologics manufacturing capability for monoclonal antibodies, bispecific antibodies, fusion proteins, conjugated proteins, and enzymes. The company’s revenue is generated by providing CDMO services for biologics development and manufacturing, including technology transfer, production, and quality assurance for pharmaceutical companies.
Who invested in Chime Biologics
4 investors across 3 rounds
See all investors in Chime Biologics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Chime Biologics
Who invested in Chime Biologics?
Chime Biologics has 4 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Chime Biologics raised?
Chime Biologics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Chime Biologics last raise money?
Chime Biologics's most recent round on record is a Series A, in Dec 2025.
What does Chime Biologics do?
Based in Wuhan, China, and founded in 2013, Chime Biologics Limited provides biopharmaceutical development and manufacturing solutions.
Where is Chime Biologics headquartered?
Chime Biologics is headquartered in Wuhan, China.
Which VCs invest in companies like Chime Biologics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Chime Biologics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Chime Biologics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.